Are stem-like cells responsible for resistance to therapy in breast cancer?

Breast Disease

Volumn 29, Issue , 2007, Pages 83-89

  O'Brien, Ciara S ^a   Farnie, Gillian ^a   Howell, Sacha J ^a   Clarke, Robert B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FULVESTRANT; LAPATINIB; MONOCLONAL ANTIBODY DC101; PACLITAXEL; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CELL FUNCTION; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TARGETING; GLIOMA; HUMAN; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERAPY RESISTANCE;

EID: 57049112020     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2008-29109     Document Type: Review

References (54)

1. D. Bonnet and J.E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med 3(7) (1997), 730-737.
2. S.K. Singh et al., Identification of a cancer stem cell in human brain tumors, Cancer Res 63(18) (2003), 5821-5828.
3. S.K. Singh et al., Identification of human brain tumour initiating cells, Nature 432(7015) (2004), 396-401.
4. M. Al-Hajj et al., From the Cover: Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci USA 100 7) (2033), 3983-3988.
5. A.T. Collins et al., Prospective identification of tumorigenic prostate cancer stem cells, Cancer Res 65(23) (2005), 10946-10951.
6. C.A. O'Brien et al., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature 445(7123) (2007), 106-110.
7. L. Ricci-Vitiani et al., Identification and expansion of human colon-cancer-initiating cells, Nature 445(7123) (2007), 111-115.
8. D. Ponti et al., Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties, Cancer Res 65(13) (2005), 5506-5511.
9. R.W. Storms et al., Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity, Proc Natl Acad Sci USA 96(16) (1999), 9118-9123.
10. C. Ginestier et al., ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome, Cell Stem Cell 1(5) (2007), 555-567.
11. R.B. Clarke et al., A putative human breast stem cell population is enriched for steroid receptor-positive cells, Dev Biol 277 2) (2005), 443-456.
12. H. Clayton, I. Titley and M. Vivanco, Growth and differentiation of progenitor/stem cells derived from the human mammary gland, Exp Cell Res 297(2) (2004), 444-460.
13. L. Patrawala et al., Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic, Cancer Res 65(14) (2005), 6207-6219.
14. (EBCTCG), E.B.C.T.C.G., Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials, Lancet 365(9472) (2005), 1687-1717.
15. M. Clarke et al., Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials, Lancet 366(9503) (2005), 2087-2106.
16. G. Farnie et al., Novel cell culture technique for primary ductal carcinoma in situ: Role of Notch and epidermal growth factor receptor signaling pathways, J Natl Cancer Inst 99(8) (2007), 616-627.
17. B. Keith and M.C. Simon, Hypoxia-inducible factors, stem cells, and cancer, Cell 129(3) (2007), 465-472.
18. W.A. Woodward et al., WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells, Proc Natl Acad Sci USA 104 2) (2007), 618-623.
19. T.M. Phillips, W.H. McBride and F. Pajonk, The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation, J Natl Cancer Inst 98(24) (2006), 1777-1785.
20. S. Bao et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature 444(7120) (2006), 756-760.
21. C.M. Fillmore and C. Kuperwasser, Human breast cancer cell lines contain stem-like cells with the capacity to selfrenew, give rise to phenotypically diverse progeny and survive chemotherapy, Breast Cancer Res 10(2) (2008), R25.
22. X. Li et al., Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy, Journal of the National Cancer Institute 100 9) (2008), 672-679.
23. A. Howell and A.M. Wardley, Overview of the impact of conventional systemic therapies on breast cancer, Endocr Relat Cancer 12 Suppl 1 (2005), S9-S16.
24. M.L. Asselin-Labat et al., Steroid hormone receptor status of mouse mammary stem cells, J Natl Cancer Inst 98(14) (2006), 1011-1014.
25. K.E. Sleeman et al., Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland, J Cell Biol 176 1) (2007), 19-26.
26. R.B. Clarke et al., Dissociation between steroid receptor expression and cell proliferation in the human breast, Cancer Res 57(22) (1997), 4987-4991.
27. T.N. Seagroves et al., C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development, Mol Endocrinol 14(3) (2000), 359-368.
28. C.M. Perou et al., Molecular portraits of human breast tumours, Nature 406(6797) (2000), 747-752.
29. T. Sorlie et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA 98(19) (2001), 10869-10874.
30. A.H. Sims et al., Origins of breast cancer subtypes and therapeutic implications, Nat Clin Pract Oncol 4(9) (2007), 516-525.
31. B.S. Shoker et al., Estrogen receptor-positive proliferating cells in the normal and precancerous breast, Am J Pathol 155(6) (1999), 1811-1815.
32. T. Sorlie et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci USA 100(14) (2003), 8418-8423.
33. M.P. Shekhar et al., Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity, Am J Pathol 170(5) (2007), 1546-1560.
34. C.K. Osborne et al., Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer, J Natl Cancer Inst 95(5) (2003), 353-361.
35. R.A. McClelland et al., Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex), Endocrinology 142(7) (2001), 2776-2788.
36. A.M. Warri et al., Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice, Int J Cancer 49(4) (1991), 616-623.
37. G. Arpino et al., Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy, J Natl Cancer Inst 99(9) (2007), 694-705.
38. J. Sims-Mourtada et al., Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport, Oncogene 26(38) (2007), 5674-5679.
39. J. Sims-Mourtada et al., Hedgehog: An attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response, Clin Cancer Res 12(21) (2006), 6565-6572.
40. M. Todaro et al., Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4, Cell Stem Cell 1(4) (2007), 389-402.
41. C. Calabrese et al., A perivascular niche for brain tumor stem cells, Cancer Cell 11(1) (2007), 69-82.
42. S. Bao et al., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor, Cancer Res 66 16) (2006), 7843-7848.
43. K. Miller et al., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med 357(26) (2007), 2666-2676.
44. C. Folkins et al., Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stemlike cell fraction in glioma xenograft tumors, Cancer Res 67(8) (2007), 3560-3564.
45. M. Garcia-Barros et al., Tumor response to radiotherapy regulated by endothelial cell apoptosis, Science 300(5622) (2003), 1155-1159.
46. S.V. Kozin et al., Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors, Cancer Res 67(11) (2007), 5076-5082.
47. R.P. Dings et al., Scheduling of radiation with angiogenesis inhibitors anginex andAvastin improves therapeutic outcome via vessel normalization, Clin Cancer Res 13(11) (2007), 3395-3402.
48. R. Ohno, N. Asou and K. Ohnishi, Treatment of acute promyelocytic leukemia: Strategy toward further increase of cure rate, Leukemia 17(8) (2003), 1454-1463.
49. X. Fan et al., Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors, Cancer Res 66 15) (2006), 7445-7452.
50. S.G. Piccirillo et al., Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells, Nature 444(7120) (2006), 761-765.
51. E.E. Bar et al., Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma, Stem Cells 25 10) (2007), 2524-2533.
52. R.C. Guzman et al., Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy, Proc Natl Acad Sci USA 96(5) (1999), 2520-2525.
53. K. Liby et al., A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland, Clin Cancer Res 13(20) (2007), 6237-6243.
54. K. Wu et al., Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade, Breast Cancer Res Treat 96(2) (2006), 147-157.